Crazy before delisting? Ruixing skyrocketed by more than 50%! European and American stock markets rose across the board, Trump praised the stock market

Original title: Crazy before delisting? Ruixing skyrocketed by more than 50%! European and American stock markets rose across the board, Trump praised the stock market
The positive news about the research and development of the new coronavirus vaccine and the restart of the European and American economies has once again ignited market optimism.
On Tuesday, EDT, the three major US stock indexes rose across the board. As of the close, the Dow rose 529.95 points, or 2.17%, to 24995.11 points; the Nasdaq rose 15.63 points, or 0.17%, to 9340.22 points; the S & P 500 index rose 36.32 points, Or 1.23%, at 2997.77 points.
In terms of sector performance, financial stocks generally rose. Citigroup rose more than 9%, Dow constituents Goldman Sachs closed up 9%, Wells Fargo Bank rose more than 8%, JP Morgan Chase closed up 7.1%, American Express closed up 5.6%.
General aviation stocks rose, United Airlines rose more than 16%, Southwest Airlines rose more than 12%, Delta Airlines rose more than 12%, American Airlines rose more than 14%.
Most of the popular Chinese stocks rose, Alibaba rose 0.96%, JD.com rose 5.41%, Baidu rose 4.88%, Weilai Automobile rose 16.97%, Pinduoduo fell 5.55%, and Ruixing Coffee rose 53.24%.
For European stocks, the main stock indexes closed up, and the British FTSE 100 index closed at 6067.76 points on the 26th, an increase of 74.48 points or 1.24% from the previous trading day. The French CAC40 index closed at 4602.24 points, an increase of 66.33 points from the previous trading day, or an increase of 1.46%. The German DAX index closed at 11,504.65 points, up 113.37 points from the previous trading day, or 1.00%.
In addition, the hope that global economic activity will become active again may drive up demand for crude oil. U.S. oil rose more than 3%. As of the close, the price of July light crude oil futures in New York rose by 1.10 US dollars, or 3.31%, to close at 34.35 US dollars per barrel. July Brent crude oil futures closed up 0.64 US dollars, an increase of 1.80%, to 36.17 US dollars / barrel.
In terms of the epidemic situation, real-time statistics released by Johns Hopkins University in the United States show that as of May 27, Beijing time, around 6.30pm, there were more than 5.55 million cases of new coronary pneumonia diagnosed globally, reaching 5555691 cases, a new one-day new An increase of 83,923 cases; cumulative deaths exceeded 340,000 cases, reaching 348,541 cases. Compared with the previous day, there were more than 83,000 newly diagnosed cases outside China, with a cumulative diagnosis of more than 5.47 million cases; there were 3630 new deaths outside China, with a cumulative death case of more than 343,000 cases.
As of 6:30 on May 27th, Beijing time, the United States had a total of 1676401 cases diagnosed and 98787 deaths. Compared with the data at 6:30 the previous day, there were 18,960 newly confirmed cases and 753 new deaths in the United States. Among them, the number of increasing cases in the United States rebounded again, with a single-day increase of 16,811 on the 26th.
In terms of economic restart, Japanese Prime Minister Shinzo Abe has announced the complete lifting of the national emergency declaration; British officials are also preparing plans to reopen non-public places, outdoor markets and car showrooms from June 1; Germany and Spain will relax travel restrictions, Other countries will gradually return to normal.
In terms of vaccine progress, Merck announced that it plans to develop two new crown vaccines. The vaccine developed by American biotechnology company Novavax will begin human testing in Australia, and preliminary results are expected in July.
In another statement, Merck and IAVI said that their coronavirus candidate vaccine will use recombinant vesicular stomatitis virus technology, which is the basis of its Ebola Zaire virus vaccine-after The author is the first rVSV vaccine approved for human use.
According to BioCentury, which tracks progress in the development of new crown vaccines and drugs, there are currently about 150 coronavirus vaccines in development worldwide. Participants include Johnson & Johnson and Pfizer, and more than 350 drugs are under development or are being studied.
Novavax (NVAX) said it has conducted the first human study of its experimental coronavirus vaccine, making it one of at least 10 vaccines currently being tested in humans worldwide.
According to reports, the company located in Gaithersburg, Maryland, said that it planned to have two